See more : Northgold AB (publ) (NG.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Hill-Rom Holdings, Inc. (HRC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hill-Rom Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Protalix BioTherapeutics, Inc. (PLX) Income Statement Analysis – Financial Results
- Sri Lakshmi Saraswathi Textiles (Arni) Limited (SLSTLQ.BO) Income Statement Analysis – Financial Results
- ALFOT Technologies Co., Ltd. (4553.TWO) Income Statement Analysis – Financial Results
- FDC Limited (FDC.NS) Income Statement Analysis – Financial Results
- Pacific Oak Strategic Opportunity REIT, Inc. (PCOK) Income Statement Analysis – Financial Results
Hill-Rom Holdings, Inc. (HRC)
About Hill-Rom Holdings, Inc.
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.02B | 2.88B | 2.91B | 2.85B | 2.74B | 2.66B | 1.99B | 1.69B | 1.72B | 1.63B | 1.59B | 1.47B | 1.39B | 1.51B | 2.02B | 1.96B | 1.94B | 1.83B | 2.04B | 1.76B | 2.11B | 2.10B | 2.05B | 2.00B | 1.78B | 1.68B | 1.62B | 1.58B | 1.45B | 1.43B | 1.20B | 1.11B | 1.14B | 884.30M | 724.60M | 641.10M | 507.60M |
| Cost of Revenue | 1.43B | 1.41B | 1.48B | 1.45B | 1.42B | 1.40B | 1.11B | 906.20M | 935.90M | 879.60M | 810.40M | 753.00M | 759.00M | 838.20M | 1.14B | 1.11B | 1.05B | 921.00M | 1.14B | 1.01B | 1.25B | 1.27B | 1.27B | 1.17B | 1.03B | 908.00M | 1.01B | 939.20M | 634.80M | 646.60M | 555.60M | 508.90M | 596.90M | 410.40M | 328.50M | 286.90M | 265.80M |
| Gross Profit | 1.59B | 1.48B | 1.43B | 1.39B | 1.32B | 1.26B | 880.30M | 779.90M | 780.30M | 754.70M | 781.30M | 716.60M | 627.90M | 669.50M | 881.10M | 849.80M | 888.00M | 908.00M | 901.00M | 748.00M | 854.00M | 826.00M | 776.00M | 834.00M | 745.00M | 776.00M | 613.00M | 637.80M | 813.10M | 783.20M | 643.30M | 597.70M | 541.40M | 473.90M | 396.10M | 354.20M | 241.80M |
| Gross Profit Ratio | 52.61% | 51.20% | 49.01% | 48.95% | 48.13% | 47.34% | 44.28% | 46.25% | 45.47% | 46.18% | 49.09% | 48.76% | 45.27% | 44.41% | 43.54% | 43.29% | 45.82% | 49.64% | 44.12% | 42.57% | 40.53% | 39.41% | 37.91% | 41.68% | 41.95% | 46.08% | 37.73% | 40.44% | 56.16% | 54.78% | 53.66% | 54.01% | 47.56% | 53.59% | 54.66% | 55.25% | 47.64% |
| Research & Development | 144.90M | 136.50M | 139.50M | 135.60M | 133.70M | 133.50M | 91.80M | 71.90M | 70.20M | 66.90M | 63.80M | 58.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 941.00M | 891.50M | 876.10M | 853.30M | 664.20M | 548.30M | 549.50M | 496.40M | 502.00M | 474.60M | 0.00 | 543.90M | 604.40M | 529.10M | 604.00M | 582.00M | 573.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 441.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 941.00M | 891.50M | 876.10M | 853.30M | 664.20M | 548.30M | 549.50M | 496.40M | 502.00M | 474.60M | 0.00 | 543.90M | 604.40M | 529.10M | 604.00M | 582.00M | 573.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 441.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 995.60M | 929.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 517.30M | 22.80M | -1.40M | 3.10M | 394.00M | 6.00M | 9.00M | 780.00M | 618.00M | 582.00M | 565.00M | 606.00M | 481.00M | 99.00M | 433.50M | 481.80M | 578.80M | 593.80M | 485.40M | 460.20M | 401.00M | 338.50M | 270.30M | 240.60M | 171.20M |
| Operating Expenses | 1.14B | 1.07B | 1.08B | 1.03B | 1.01B | 986.80M | 756.00M | 620.20M | 619.70M | 563.30M | 565.80M | 532.90M | 517.30M | 566.70M | 603.00M | 532.20M | 998.00M | 588.00M | 582.00M | 780.00M | 618.00M | 582.00M | 565.00M | 606.00M | 481.00M | 540.00M | 433.50M | 481.80M | 578.80M | 593.80M | 485.40M | 460.20M | 401.00M | 338.50M | 270.30M | 240.60M | 171.20M |
| Cost & Expenses | 2.57B | 2.47B | 2.56B | 2.48B | 2.43B | 2.39B | 1.86B | 1.53B | 1.56B | 1.44B | 1.38B | 1.29B | 1.28B | 1.40B | 1.75B | 1.65B | 2.05B | 1.51B | 1.72B | 1.79B | 1.87B | 1.85B | 1.84B | 1.77B | 1.51B | 1.45B | 1.45B | 1.42B | 1.21B | 1.24B | 1.04B | 969.10M | 997.90M | 748.90M | 598.80M | 527.50M | 437.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 65.60M | 74.00M | 89.60M | 95.00M | 88.90M | 90.40M | 18.40M | 9.80M | 9.50M | 6.50M | 8.50M | 8.70M | 10.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 185.80M | 178.80M | 194.80M | 196.50M | 210.80M | 209.00M | 118.20M | 106.40M | 116.80M | 111.70M | 103.90M | 99.70M | 100.20M | 112.80M | 107.30M | 108.80M | 114.00M | 108.00M | 75.00M | 71.00M | 100.00M | 89.00M | 98.00M | 149.00M | 102.00M | 99.00M | 127.60M | 97.50M | 112.70M | 115.30M | 95.00M | 94.00M | 81.00M | 68.80M | 54.40M | 49.30M | 28.30M |
| EBITDA | 554.20M | 524.00M | 493.00M | 488.70M | 484.00M | 439.00M | 202.60M | 231.40M | 270.30M | 281.70M | 271.90M | 290.60M | -268.20M | 253.80M | 398.80M | 447.50M | 6.00M | 338.00M | 313.00M | 50.00M | 323.00M | 329.00M | 293.00M | 442.00M | 361.00M | 332.00M | 297.40M | 242.30M | 347.70M | 297.30M | 240.70M | 220.40M | 208.30M | 189.20M | 164.80M | 149.20M | 90.00M |
| EBITDA Ratio | 18.36% | 18.19% | 16.96% | 17.16% | 17.64% | 16.53% | 10.19% | 13.72% | 15.75% | 17.24% | 17.08% | 19.77% | -19.34% | 16.83% | 19.71% | 22.80% | 0.31% | 18.48% | 15.33% | 2.85% | 15.33% | 15.70% | 14.31% | 22.09% | 20.33% | 19.71% | 18.30% | 15.36% | 24.01% | 20.79% | 20.08% | 19.92% | 18.30% | 21.40% | 22.74% | 23.27% | 17.73% |
| Operating Income | 447.60M | 409.20M | 344.50M | 367.10M | 310.80M | 270.20M | 124.30M | 159.70M | 160.60M | 191.40M | 215.50M | 183.70M | 110.60M | 102.80M | 278.10M | 317.60M | -110.00M | 320.00M | 319.00M | -32.00M | 236.00M | 244.00M | 211.00M | 228.00M | 264.00M | 236.00M | 179.50M | 156.10M | 234.30M | 189.40M | 157.90M | 137.50M | 140.40M | 135.40M | 125.80M | 113.60M | 70.60M |
| Operating Income Ratio | 14.83% | 14.20% | 11.85% | 12.89% | 11.33% | 10.18% | 6.25% | 9.47% | 9.36% | 11.71% | 13.54% | 12.50% | 7.97% | 6.82% | 13.74% | 16.18% | -5.68% | 17.50% | 15.62% | -1.82% | 11.20% | 11.64% | 10.31% | 11.39% | 14.86% | 14.01% | 11.05% | 9.90% | 16.18% | 13.25% | 13.17% | 12.43% | 12.33% | 15.31% | 17.36% | 17.72% | 13.91% |
| Total Other Income/Expenses | -144.80M | -138.00M | -135.90M | -169.90M | -127.80M | -131.90M | -59.20M | -44.50M | -16.60M | -27.90M | -55.80M | -800.00K | -489.40M | -10.50M | 13.40M | 21.40M | -6.00M | -12.00M | -37.00M | -3.00M | -13.00M | -4.00M | -16.00M | 65.00M | -5.00M | -3.00M | -9.70M | -11.30M | -12.70M | -18.10M | -12.20M | -11.10M | -13.10M | -15.00M | -15.40M | -13.70M | -8.90M |
| Income Before Tax | 302.80M | 271.20M | 208.60M | 197.20M | 183.00M | 138.30M | 65.10M | 115.20M | 144.00M | 163.50M | 159.70M | 182.90M | -378.80M | 92.30M | 291.50M | 339.00M | -116.00M | 308.00M | 282.00M | -35.00M | 223.00M | 240.00M | 195.00M | 293.00M | 259.00M | 233.00M | 169.80M | 144.80M | 221.60M | 171.30M | 145.70M | 126.40M | 127.30M | 120.40M | 110.40M | 99.90M | 61.70M |
| Income Before Tax Ratio | 10.03% | 9.41% | 7.18% | 6.92% | 6.67% | 5.21% | 3.27% | 6.83% | 8.39% | 10.00% | 10.03% | 12.45% | -27.31% | 6.12% | 14.40% | 17.27% | -5.99% | 16.84% | 13.81% | -1.99% | 10.58% | 11.45% | 9.53% | 14.64% | 14.58% | 13.84% | 10.45% | 9.18% | 15.30% | 11.98% | 12.15% | 11.42% | 11.18% | 13.62% | 15.24% | 15.58% | 12.16% |
| Income Tax Expense | 54.30M | 48.20M | 56.40M | -55.20M | 50.70M | 15.50M | 18.30M | 54.60M | 39.00M | 42.70M | 26.20M | 56.90M | 26.20M | 25.20M | 100.90M | 117.50M | -20.00M | 120.00M | 100.00M | -25.00M | 53.00M | 86.00M | 71.00M | 109.00M | 102.00M | 93.00M | 79.90M | 55.30M | 89.10M | 65.80M | 56.50M | 50.70M | 52.30M | 50.70M | 53.00M | 49.40M | 28.90M |
| Net Income | 248.50M | 223.00M | 152.20M | 252.40M | 133.60M | 124.10M | 47.70M | 60.60M | 105.00M | 120.80M | 133.30M | 125.30M | -405.00M | 115.80M | 190.60M | 221.20M | -94.00M | 110.00M | 138.00M | -10.00M | 170.00M | 154.00M | 124.00M | 184.00M | 157.00M | 140.00M | 89.90M | 89.50M | 145.90M | 116.20M | 89.20M | 75.70M | 75.00M | 69.70M | 57.40M | 50.50M | 32.80M |
| Net Income Ratio | 8.23% | 7.74% | 5.24% | 8.86% | 4.87% | 4.67% | 2.40% | 3.59% | 6.12% | 7.39% | 8.37% | 8.53% | -29.20% | 7.68% | 9.42% | 11.27% | -4.85% | 6.01% | 6.76% | -0.57% | 8.07% | 7.35% | 6.06% | 9.20% | 8.84% | 8.31% | 5.53% | 5.68% | 10.08% | 8.13% | 7.44% | 6.84% | 6.59% | 7.88% | 7.92% | 7.88% | 6.46% |
| EPS | 3.72 | 3.32 | 2.25 | 3.73 | 2.03 | 1.89 | 0.73 | 1.06 | 1.79 | 1.99 | 2.16 | 2.00 | -6.47 | 1.85 | 3.08 | 3.60 | -1.52 | 1.77 | 2.22 | -0.16 | 2.71 | 2.45 | 1.87 | 2.72 | 2.28 | 2.02 | 1.27 | 1.26 | 2.04 | 1.62 | 1.23 | 1.03 | 1.01 | 0.93 | 0.76 | 0.66 | 0.42 |
| EPS Diluted | 3.72 | 3.32 | 2.25 | 3.73 | 1.99 | 1.86 | 0.73 | 1.04 | 1.74 | 1.94 | 2.09 | 1.97 | -6.47 | 1.85 | 3.07 | 3.59 | -1.52 | 1.75 | 2.22 | -0.16 | 2.71 | 2.45 | 1.87 | 2.72 | 2.28 | 2.01 | 1.27 | 1.26 | 2.04 | 1.62 | 1.23 | 1.03 | 1.01 | 0.93 | 0.76 | 0.66 | 0.42 |
| Weighted Avg Shares Out | 66.85M | 67.21M | 67.66M | 67.61M | 65.81M | 65.71M | 65.17M | 57.44M | 58.52M | 60.80M | 61.69M | 62.79M | 62.57M | 62.43M | 61.82M | 61.45M | 61.77M | 62.24M | 62.03M | 62.70M | 62.80M | 62.90M | 66.30M | 67.60M | 68.80M | 69.47M | 70.80M | 71.30M | 71.52M | 71.73M | 72.66M | 73.22M | 74.23M | 74.59M | 75.54M | 77.10M | 77.75M |
| Weighted Avg Shares Out (Dil) | 66.85M | 67.21M | 67.66M | 67.61M | 67.23M | 66.60M | 65.17M | 58.52M | 60.25M | 62.36M | 63.90M | 63.74M | 62.58M | 62.62M | 62.12M | 61.58M | 61.77M | 62.73M | 62.18M | 62.70M | 62.80M | 62.90M | 66.30M | 67.60M | 68.80M | 69.66M | 70.80M | 71.30M | 71.52M | 71.73M | 72.66M | 73.22M | 74.23M | 74.59M | 75.54M | 77.10M | 77.75M |
7 Stocks to Buy That Investors Should Keep ‘Holding' for Years to Come
When you're looking for stocks to buy that you can hold for years to come, what's in a name is sometimes all you need to find your way. The post 7 Stocks to Buy That Investors Should Keep ‘Holding' for...
Hill-Rom (HRC) New LT Strategy Aids, Y/Y Comparisons Ail
Hill-Rom's (HRC) newly initiated long-term growth strategies through fiscal 2022, focusing on all four strategic priorities, look attractive at this moment.
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Contact the Firm
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Triple-S Management Corporation (NYSE: GTS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...
SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua...
Hill-Rom Stock Rises After Baxter's Revised Bid
Last month we discussed that the stock price of Hill-Rom Holdings, best known for its hospital beds and patient mobility solutions, will likely see further gains if Baxter were to revise its acquisition bid. Baxter has now revised its offer...
HILL-ROM HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hill-Rom Holdings, Inc. - HRC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hill-Rom Holdings, Inc. (NYSE: HRC) to Baxter International Inc. (NYSE: BAX)....
HILL-ROM HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hill-Rom Holdings, Inc. - HRC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hill-Rom Holdings, Inc. (NYSE: HRC) to Baxter International Inc. (NYSE: BAX)....
Baxter (BAX) to Benefit From Hill-Rom Buyout: Here's How
Baxter's (BAX) latest acquisition is likely to accelerate its digitally-enabled connected care solutions across the care continuum and enhance patient services.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Hill-Rom Holdings, Inc.
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hill-Rom Holdings, Inc. ("Hill-Rom" or the "Company") (NYSE: HRC) in connection with the proposed...
Source: https://incomestatements.info
Category: Stock Reports